Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael F McDermott

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|August 4, 2009
Rilonacept in the treatment of chronic inflammatory disordersMichael F McDermott
Trends in Immunology|August 25, 2004
A common pathway in periodic fever syndromesMichael F McDermott
Nature Reviews. Rheumatology|March 12, 2024
A nosology of immune diseases from deep immunophenotypingMichael F McDermott
Trends in Molecular Medicine|December 10, 2002
Genetic clues to understanding periodic fevers, and possible therapiesMichael F McDermott
Current Opinion in Rheumatology|December 2, 2016
Lessons from characterization and treatment of the autoinflammatory syndromesIvona Aksentijevich, Michael F McDermott
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2003
BMS-561392. Bristol-Myers SquibbMartin Grootveld, Michael F McDermott
Plos Medicine|September 1, 2006
A proposed classification of the immunological diseasesDennis McGonagle, Michael F McDermott
Nature Reviews. Rheumatology|December 24, 2014
Clinical genetics in 2014: New monogenic diseases span the immunological disease continuumSinisa Savic, Michael F McDermott
Current Opinion in Molecular Therapeutics|December 15, 2010
Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular diseaseJanina Geiler, Michael F McDermott
Bioscience Reports|June 22, 2017
Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathwayCamilla West, Michael F McDermott
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Drugs of Today (Barcelona, Spain : 1998)|August 4, 2009
Rilonacept in the treatment of chronic inflammatory disordersMichael F McDermott
Trends in Immunology|August 25, 2004
A common pathway in periodic fever syndromesMichael F McDermott
Nature Reviews. Rheumatology|March 12, 2024
A nosology of immune diseases from deep immunophenotypingMichael F McDermott
Trends in Molecular Medicine|December 10, 2002
Genetic clues to understanding periodic fevers, and possible therapiesMichael F McDermott
Current Opinion in Rheumatology|December 2, 2016
Lessons from characterization and treatment of the autoinflammatory syndromesIvona Aksentijevich, Michael F McDermott
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2003
BMS-561392. Bristol-Myers SquibbMartin Grootveld, Michael F McDermott
Plos Medicine|September 1, 2006
A proposed classification of the immunological diseasesDennis McGonagle, Michael F McDermott
Nature Reviews. Rheumatology|December 24, 2014
Clinical genetics in 2014: New monogenic diseases span the immunological disease continuumSinisa Savic, Michael F McDermott
Current Opinion in Molecular Therapeutics|December 15, 2010
Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular diseaseJanina Geiler, Michael F McDermott
Bioscience Reports|June 22, 2017
Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathwayCamilla West, Michael F McDermott
Pageof 11